Therapeutic Advances in Neurological Disorders This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Management of women with multiple sclerosis through pregnancy and after childbirth
Multiple sclerosis (MS) is a major acquired neurologic disease of young adults. The prototypic patient is a young woman of reproductive age. Gender preference is becoming more pronounced, since MS is increasing specifically among women. Any healthcare provider who deals with MS must be prepared to discuss pregnancy issues, and provide appropriate counseling. This is now complicated by the availability of multiple treatment options. There is growing literature on which to base recommendations, particularly regarding washout periods. After a brief background introduction, this review will discuss state-of-the-art family plan...
Source: Therapeutic Advances in Neurological Disorders - March 22, 2016 Category: Neurology Authors: Coyle, P. K. Tags: Reviews Source Type: research

Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series
We describe six cases of patients with relapsing-remitting MS who had previously experienced detrimental mood changes with MP treatment. Some of these patients had previous histories of mood disorders or other neuropsychiatric symptoms prior to MS diagnosis. All six patients were subsequently treated with repository corticotropin injection for MS exacerbations and each demonstrated improvements in MS symptoms. This clinical experience suggests that repository corticotropin injection should be considered as an alternative for patients who do not tolerate corticosteroids or have difficulties associated with intravenous medic...
Source: Therapeutic Advances in Neurological Disorders - March 22, 2016 Category: Neurology Authors: Murray, S., Woo, A. Tags: Reviews Source Type: research

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica
Neuromyelitis optica spectrum disorders (NMOSDs) is a new concept which includes classical neuromyelitis optica (NMO) and partial forms of NMO such as recurrent optic neuritis with positive aquaporin-4 antibodies (AQP4) or brainstem symptoms (intractable hiccups or vomiting). This disease is clearly distinguished from multiple sclerosis (MS) and the therapeutic approach is clearly different. Rituximab is actually considered to be one of the most efficient treatments of NMOSD, even if class I studies are clearly lacking. In the present review, we describe the state of the art about rituximab treatment in NMOSD, including ad...
Source: Therapeutic Advances in Neurological Disorders - March 22, 2016 Category: Neurology Authors: Collongues, N., de Seze, J. Tags: Reviews Source Type: research

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry
Conclusions: The management of patients with MMN in everyday clinical practice demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting the recommended practice of determining treatment dose on an individual patient basis. The improvements in muscle strength and reduction in disability, accompanied by increased QoL, strengthen the case for use of IG as a maintenance treatment for MMN. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 22, 2016 Category: Neurology Authors: Stangel, M., Gold, R., Pittrow, D., Baumann, U., Borte, M., Fasshauer, M., Hensel, M., Huscher, D., Reiser, M., Sommer, C. Tags: Original Research Source Type: research

A pilot study on the benefit of cognitive rehabilitation in Parkinsons disease
Conclusions: The efficacy of the applied computerized cognitive training tool BrainStim could be verified in patients with PD and healthy age-matched controls. The preliminary findings highlighted the suitability of a specific cognitive intervention to improve cognitive inefficiencies in patients with PD as well as in healthy older people. Further research on cognitive training in combination with PD drug therapy is needed to better understand the mutual interaction and to offer optimal therapeutic approaches to patients. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 22, 2016 Category: Neurology Authors: Adamski, N., Adler, M., Opwis, K., Penner, I.-K. Tags: Original Research Source Type: research

Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials and their extensions, plus postmarketing studies that contribute to characterizing the efficacy and safety profile of fingolimod in patients with relapsing forms of multiple sclerosis. Data from the controlled, phase III, pivotal studies [FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Mul...
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Khatri, B. O. Tags: Reviews Source Type: research

Management of epilepsy during pregnancy: an update
The clinical management of women with epilepsy on antiepileptic drugs (AEDs) during pregnancy presents unique challenges. The goal of treatment is optimal seizure control with minimal in utero fetal exposure to AEDs in an effort to reduce the risk of structural and neurodevelopmental teratogenic effects. This paper reviews the following key issues pertaining to women with epilepsy during pregnancy: AED pharmacokinetics; clinical management of AEDs; seizure frequency; major congenital malformation; neurodevelopmental outcomes; perinatal complications; and breast feeding. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Patel, S. I., Pennell, P. B. Tags: Reviews Source Type: research

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease
Conclusions: Further study of FLU for breakthrough disease in patients with RRMS is warranted. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Greenberg, S. J., Zivadinov, R., Lee-Kwen, P., Sharma, J., Planter, M., Umhauer, M., Glenister, N., Bakshi, R. Tags: Original Research Source Type: research

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany
Conclusions: Most attributes examined in this experiment had an influence on patient preference. Patients placed a significant value on improvements in the frequency of dosing and disability progression. Results suggest that changes in injection frequency can be as important as changes in efficacy and safety attributes. Understanding which attributes of injectable therapies influence patient preference could potentially improve outcomes and adherence in patients with multiple sclerosis. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Poulos, C., Kinter, E., Yang, J.-C., Bridges, J. F. P., Posner, J., Gleissner, E., Mühlbacher, A., Kieseier, B. Tags: Original Research Source Type: research

Nontraumatic spinal cord injury at the neurological intensive care unit: spectrum, causes of admission and predictors of mortality
Conclusions: Patients with NTSCI account for a subset of patients admitted to the NICU and are at risk for adverse outcome. A better understanding of predisposing conditions and further knowledge of management of critically ill patients with NTSCI is mandatory. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Grassner, L., Marschallinger, J., Dünser, M. W., Novak, H. F., Zerbs, A., Aigner, L., Trinka, E., Sellner, J. Tags: Original Research Source Type: research

Outcome and periprocedural time management in referred versus directly admitted stroke patients treated with thrombectomy
Conclusions: Our results show that a drip-and-ship thrombectomy concept can be effectively organized in a metropolitan stroke network. Every effort should be made to speed up the emergency interfacility transfer to a neurointerventional centre in stroke patients eligible for thrombectomy after initial brain imaging. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - March 4, 2016 Category: Neurology Authors: Weber, R., Reimann, G., Weimar, C., Winkler, A., Berger, K., Nordmeyer, H., Hadisurya, J., Brassel, F., Kitzrow, M., Krogias, C., Weber, W., Busch, E. W., Eyding, J., on behalf of the Neurovascular Net Ruhr Tags: Original Research Source Type: research

Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab
(Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - December 18, 2015 Category: Neurology Authors: Magira, E. E., Alexopoulos, H., Charitatos, E., Michas, D., Dalakas, M. C. Tags: Letter to the Editor Source Type: research

The optimal management of headaches in children and adolescents
The recognition of the diagnosis of migraine in children is increasing. Early and aggressive treatment of migraine in this population with the use of over-the-counter medications has proven effective. The off-label use of many migraine-specific medications is often accepted in the absence of sufficient evidenced-based trials. Mild to severe cases of migraine should be treated with nonsteroidal anti-inflammatory drugs, with triptans used in moderate to severe headaches unresponsive to over-the-counter therapy. Rescue medication including dihydroergotamine [DHE] should be used for status migrainosus, preferably in the hospit...
Source: Therapeutic Advances in Neurological Disorders - December 18, 2015 Category: Neurology Authors: Kacperski, J., Kabbouche, M. A., OBrien, H. L., Weberding, J. L. Tags: Reviews Source Type: research

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune diseases including MS lay near at hand. Rituximab was the first therapeutic B-cell-depleting chimeric monoclonal antibody to be used successfully in MS. Ocrelizumab, a second-generation humanized anti-CD20 antibody, was explored in a large phase II, randomized, placebo-controlled multicentre trial in patients...
Source: Therapeutic Advances in Neurological Disorders - December 18, 2015 Category: Neurology Authors: Sorensen, P. S., Blinkenberg, M. Tags: Reviews Source Type: research

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
Multiple sclerosis (MS) is a common and chronic central nervous system (CNS) demyelinating disease and a leading cause of permanent disability. Patients most often present with a relapsing–remitting disease course, typically progressing over time to a phase of relentless advancement in secondary progressive MS (SPMS), for which approved disease-modifying therapies are limited. In this review, we summarize the pathophysiological mechanisms involved in the development of SPMS and the rationale and clinical potential for natalizumab, which is currently approved for the treatment of relapsing forms of MS, to exert benefi...
Source: Therapeutic Advances in Neurological Disorders - December 18, 2015 Category: Neurology Authors: Sellebjerg, F., Cadavid, D., Steiner, D., Villar, L. M., Reynolds, R., Mikol, D. Tags: Reviews Source Type: research